The Council on Drugs of the American Medical Association has long cooperated with drug manufacturers in the selection of nonproprietary names for single entity drugs. The United States Pharmacopeia also has had a long-standing interest in nonproprietary drug nomenclature, because the names selected generally become the USP titles for the drugs concerned. The AMA and the USP have recently joined forces in a selection program.
A description of the negotiation process is given in "Current Procedures of the AMA-USP Cooperative Program in the Consideration of Proposed Nonproprietary Names for Drugs," copies of which are available on request from the Council.
In this issue of The Journal, p. 739, the Council on Drugs initiates a new feature, a listing of nonproprietary names newly adopted by the AMAUSP Nomenclature Committee.
The purpose of publishing such a list at this time is twofold: (1) to promptly provide medical educators and physicians with basic